litlas
Log inCreate account

Solko W. Schalm

Active 1976–2024

77
Papers
19,028
Citations
75
h-index
76
i10-index

Citations

Citations per year for Solko W. Schalm1977: 3 citations1978: 1 citations1979: 2 citations1980: 9 citations1981: 11 citations1982: 3 citations1983: 5 citations1984: 6 citations1985: 2 citations1986: 4 citations1987: 4 citations1988: 2 citations1989: 10 citations1990: 7 citations1991: 4 citations1992: 5 citations1993: 8 citations1994: 10 citations1995: 43 citations1996: 34 citations1997: 56 citations1998: 72 citations1999: 106 citations2000: 142 citations2001: 180 citations2002: 171 citations2003: 191 citations2004: 164 citations2005: 177 citations2006: 151 citations2007: 210 citations2008: 215 citations2009: 214 citations2010: 189 citations2011: 175 citations2012: 152 citations2013: 102 citations2014: 117 citations2015: 101 citations2016: 78 citations2017: 64 citations2018: 72 citations2019: 231 citations2020: 175 citations2021: 134 citations2022: 103 citations2023: 64 citations2024: 125 citations2025: 35 citations2026: 1 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,241 citing papers, 22.4% of this breakdownUnited Kingdom: 455 citing papers, 8.2% of this breakdownGermany: 364 citing papers, 6.6% of this breakdownItaly: 360 citing papers, 6.5% of this breakdownChina: 324 citing papers, 5.8% of this breakdownFrance: 259 citing papers, 4.7% of this breakdownJapan: 247 citing papers, 4.5% of this breakdownCanada: 231 citing papers, 4.2% of this breakdownNetherlands: 217 citing papers, 3.9% of this breakdownSpain: 170 citing papers, 3.1% of this breakdownTaiwan: 133 citing papers, 2.4% of this breakdownAustralia: 115 citing papers, 2.1% of this breakdown
0%22.4%Other 25.6%

Institutions

Fields

  • Medicine88.1%
  • Pharmacology, Toxicology and Pharmaceutics3.7%
  • Biochemistry, Genetics and Molecular Biology3.2%
  • Neuroscience1.8%
  • Immunology and Microbiology1.1%
  • Nursing0.6%
  • Other1.5%

Topics

  • Liver Disease Diagnosis and Treatment14.7%
  • Hepatitis C virus research14%
  • Hepatitis B Virus Studies11.5%
  • Liver Disease and Transplantation7.6%
  • Liver Diseases and Immunity7.5%
  • Hepatitis Viruses Studies and Epidemiology3.7%
  • Other41%

Coauthors

All papers

Open in search
  1. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

    Authors: Fernando Álvarez, P. A. Berg, Francesco B. Bianchi, Leonardo Bianchi, A K Burroughs, Eduardo Luiz Rachid Cançado, Roger W. Chapman, W. G. E. Cooksley, Albert J. Czaja, Valeer Desmet, Peter T. Donaldson, A.L.W.F. Eddleston, Leonardo Fainboim, Jenny Heathcote, J C Homberg, Jay H. Hoofnagle, Shinichi Kakumu, E. L. Krawitt, I.R. Mackay, R. N. M. MacSween, Willis C. Maddrey, Michael P. Manns, Ian G. McFarlane, K. H. Meyer zum Büschenfelde, Giorgina Mieli‐Vergani, Y Nakanuma, Mikio Nishioka, Edward Penner, Gilda Porta, Bernard Portmann, W D Reed, Joan Rodés, Solko W. Schalm, P. J. Scheuer, E. Schrumpf, Takeshi Seki, G Toda, Takashi Tsuji, Niels Tygstrup, D. Vergani, Mikio Zeniya - Journal of Hepatology 1999 cited by 2,915

  2. Acute liver failure: redefining the syndromes

    Authors: R. B. Williams, Solko W. Schalm, John G. O’Grady - The Lancet 1993 cited by 961

  3. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

    Authors: Harry L.A. Janssen, Monika van Zonneveld, Hakan Şentürk, Stefan Zeuzem, Ulus Salih Akarca, Yılmaz Çakaloğlu, Christopher Simon, Thomas M. K. So, Guido Gerken, Robert A. de Man, Hubert G.M. Niesters, Pieter E. Zondervan, Bettina E. Hansen, Solko W. Schalm - The Lancet 2005 cited by 1,163

  4. Treatment with Peg-Interferon alpha-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype

    Authors: Hajo J. Flink, Monika van Zonneveld, Bettina E. Hansen, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, for the HBV 99-01 Study Group* - The American Journal of Gastroenterology 2006 cited by 261

  5. Occurrence of hepatocellular carcinoma and decompensation in western european patients with cirrhosis type B

    Authors: G. Fattovich, G. Giustina, Solko W. Schalm, Stephanos J. Hadziyannis, J.M. Sánchez-Tapias, Piero Luigi Almasio, Erik Christensen, Kim Krogsgaard, Françoise Degos, Miguel Carneiro de Moura, Antonio Solinas, Franco Noventa, G. Realdi - Hepatology 1995 cited by 373

  6. The prognostic significance of subclinical hepatic encephalopathy

    Authors: Ieneke J. C. Hartmann, Michael Groeneweg, Juan C. Quero, Sylvia J. Beijeman, Robert A. de Man, Wim C.J. Hop, Solko W. Schalm - The American Journal of Gastroenterology 2000 cited by 241

  7. Hemostasis and Fibrinolysis in Severe Liver Failure and Their Relation to Hemorrhage

    Authors: Anton L. Boks, E.J.P. Brommer, Solko W. Schalm, Huub H.D.M. van Vliet - Hepatology 1986 cited by 191

  8. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

    Authors: Felix E. de Jongh, Harry L.A. Janssen, Robert A. de Man, Wim C.J. Hop, Solko W. Schalm, M. van Blankenstein - Gastroenterology 1992 cited by 424

  9. Suicide associated with alfa-interferon therapy for chronic viral hepatitis

    Authors: Harry L.A. Janssen, Johannes T. Brouwer, Rose C. van der Mast, Solko W. Schalm - Journal of Hepatology 1994 cited by 233

  10. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double‐blind, randomized, placebo‐controlled phase I/II trial

    Authors: Tekla Gj Van Rossum, Arnold G. Vulto, Wim C.J. Hop, Johannes T. Brouwer, Hubert G.M. Niesters, Solko W. Schalm - Journal of Gastroenterology and Hepatology 1999 cited by 180

  11. Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients

    Authors: Pieter C. J. ter Borg, Solko W. Schalm, Bettina E. Hansen, Henk R. van Buuren - The American Journal of Gastroenterology 2006 cited by 162

  12. Determinants of quality of life in chronic liver patients

    Authors: Jolie J. Gutteling, Robert A. de Man, Simone M. van der Plas, Solko W. Schalm, Jan J.V. Busschbach, Anne‐Sophie Darlington - Alimentary Pharmacology & Therapeutics 2006 cited by 125

  13. Overt hepatic encephalopathy precipitated by zinc deficiency

    Authors: Carin C.D. van der Rijt, Solko W. Schalm, Han Schat, Karin Foeken, G. de Jong - Gastroenterology 1991 cited by 93

  14. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study

    Authors: Frank H.J. Wolfhagen, Hubert J.F. van Hoogstraten, Henk R. van Buuren, Gerard P. van Berge-Henegouwen, Fiebo J.W. ten Kate, Wim C.J. Hop, Egbert W. van der Hoek, Marjo J. Kerbert, Hans H. van Lijf, Janny W. den Ouden, Adelbert M. Smit, Richard A. de Vries, R.A.A. van Zanten, Solko W. Schalm - Journal of Hepatology 1998 cited by 84

  15. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study

    Authors: Hubert J van Hoogstraten, Frank P. Vleggaar, Greet J. Boland, W. Van Steenbergen, Pieter H. Griffioen, Wim C.J. Hop, Jan van Hattum, G. P. van Berge Henegouwen, Solko W. Schalm, Henk R. van Buuren, Belgian-Dutch PSC Study Group - The American Journal of Gastroenterology 2000 cited by 83

  16. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B

    Authors: Monika van Zonneveld, Pieter Honkoop, Bettina E. Hansen, Hubert G.M. Niesters, Sarwa Darwish Murad, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen - Hepatology 2004 cited by 324

  17. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study

    Authors: G. Realdi, The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP), Giovanna Fattovich, Stephanos J. Hadziyannis, Solko W. Schalm, Piero Luigi Almasio, J.M. Sánchez-Tapias, Erik Christensen, G. Giustina, Franco Noventa - Journal of Hepatology 1994 cited by 306

  18. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

    Authors: Bart J. Veldt, Wendong Chen, Jenny Heathcote, Heiner Wedemeyer, Juerg Reichen, Peter Hofmann, Robert J. de Knegt, Stefan Zeuzem, Michael P. Manns, Bettina E. Hansen, Solko W. Schalm, Harry L.A. Janssen - Hepatology 2008 cited by 285

  19. Screening of subclinical hepatic encephalopathy

    Authors: Michael Groeneweg, Wendy Moerland, Juan C. Quero, Wim C.J. Hop, Paul F. M. Krabbe, Solko W. Schalm - Journal of Hepatology 2000 cited by 207

  20. Benign versus Malignant Hepatic Nodules: MR Imaging Findings with Pathologic Correlation

    Authors: Shahid M. Hussain, Pieter E. Zondervan, Jan N.M. IJzermans, Solko W. Schalm, Rob A. de Man, Gabriël P. Krestin - Radiographics 2002 cited by 198

  21. Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis† ‡ §

    Authors: Erik H.C.J. Buster, Bettina E. Hansen, Marı́a Buti, Jean Delwaide, Claus Niederau, P. Michielsen, Robert Flisiak, Pieter E. Zondervan, Solko W. Schalm, Harry L.A. Janssen - Hepatology 2007 cited by 115

  22. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial

    Authors: Hans Orlent, Bettina E. Hansen, Marc Willems, Johannes T. Brouwer, Roman Huber, Gerd A. Kullak‐Ublick, Guido Gerken, Stefan Zeuzem, Frederik Nevens, Wanda Tielemans, Pieter E. Zondervan, Martin Lagging, Johan Westin, Solko W. Schalm - Journal of Hepatology 2006 cited by 79

  23. Mitochondrial Injury Lessons from the Fialuridine Trial

    Authors: Pieter Honkoop, H.R. Scholte, Robert A. de Man, Solko W. Schalm - Drug Safety 1997 cited by 75

  24. Subclinical hepatic encephalopathy impairs daily functioning

    Authors: Michael Groeneweg, Juan C. Quero, Ilone De Bruijn, Ieneke J. C. Hartmann, Marie‐Louise Essink‐Bot, Wim C.J. Hop, Solko W. Schalm - Hepatology 1998 cited by 503